Emyria losses deepen as drug development takes centre stage by Steve Jones March 1, 2022March 2, 2022 Emyria saw sales revenue decline by a third in the first six months of the financial […]
TGA rejects move to down-schedule MDMA and psilocybin by Martin Lane December 16, 2021December 17, 2021
TGA releases findings on MDMA and psilocybin as mental health treatments by Martin Lane October 5, 2021October 5, 2021
Company news: Emyria; Medibis; Incannex; Eqalis; Greenfern; Creso Pharma; Highlands Investments by Martin Lane August 12, 2021August 12, 2021
